{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T02:56:20Z","timestamp":1789440980254,"version":"build-2803163510"},"reference-count":51,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T00:00:00Z","timestamp":1767571200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>The therapeutic landscape of allergic diseases has been transformed by the advent of biologics targeting key immunologic pathways. These therapies offer disease-modifying potential across a spectrum of conditions including asthma, atopic dermatitis, eosinophilic esophagitis, chronic rhinosinusitis with nasal polyps, and food allergy. However, their high cost, limited long-term safety data in some populations, and evolving eligibility criteria raise critical questions about when biologics such as monoclonal antibodies are truly warranted, especially in the context of food allergy. Agents such as omalizumab have demonstrated efficacy in raising the threshold of allergic response with monotherapy and during oral immunotherapy, improving safety profiles and accelerating desensitization. Recent developments in pharmaceutical-grade food immunotherapy and adjunctive\/alternative biologic use further complicate decision-making. This expanding therapeutic toolbox necessitates a critical reassessment of when biologics are justified as front-line in allergic diseases such as food allergy. Monoclonal antibodies, in particular, are usually reserved for step-wise treatment of other diseases. It is important to have ongoing assessments as to which new and upcoming treatment modalities should be first-line. As food allergy management becomes increasingly interventional, providers must weigh the benefits of biologic therapies against real-world feasibility, health economics, and patient preference among other alternatives. Here, we discuss the current management of IgE-mediated food allergy as well as emerging therapeutics including immunotherapies and biologics. We evaluate the positioning of omalizumab in food allergy, compared with other biologics and off the shelf food-based approaches used in food allergy, and discuss clinical and research implications.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1746790","type":"journal-article","created":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T05:29:47Z","timestamp":1767590987000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Considerations for biologics as front-line treatment in allergic diseases"],"prefix":"10.3389","volume":"16","author":[{"given":"Akash","family":"Kothari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia E. M.","family":"Upton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2312382","article-title":"Omalizumab for the treatment of multiple food allergies","volume":"390","author":"Wood","year":"2024","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2205982","article-title":"Dupilumab in adults and adolescents with eosinophilic esophagitis","volume":"387","author":"Dellon","year":"2022","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1056\/NEJMoa1812856","article-title":"AR101 oral immunotherapy for peanut allergy","volume":"379","author":"Vickery","year":"2018","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1700366","article-title":"Two phase 3 trials of dupilumab versus placebo in atopic dermatitis","volume":"376","author":"Simpson","year":"2017","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1111\/all.16420","article-title":"Dupilumab as an adjunct to oral immunotherapy in pediatric patients with peanut allergy","volume":"80","author":"Chinthrajah","year":"2025","journal-title":"Allergy"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/all.16404","article-title":"Efficacy and safety of dupilumab in children with peanut allergy: A multicenter, open-label, phase II study","volume":"80","author":"Sindher","year":"2025","journal-title":"Allergy"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/all.15749","article-title":"An update on recent developments and highlights in food allergy","volume":"78","author":"Locke","year":"2023","journal-title":"Allergy: Eur J Allergy Clin Immunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)02390-4","article-title":"Efficacy and safety of oral immunotherapy in children aged 1\u20133 years with peanut allergy (the Immune Tolerance Network IMPACT trial): a randomised placebo-controlled study","volume":"399","author":"Jones","year":"2022","journal-title":"Lancet"},{"key":"B9","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.jaci.2009.05.022","article-title":"Clinical efficacy and immune regulation with peanut oral immunotherapy","volume":"124","author":"Jones","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.jaip.2018.06.016","article-title":"Quality of life of food-allergic patients before, during, and after oral immunotherapy","volume":"7","author":"Epstein-Rigbi","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/all.70046","article-title":"Systematic review and meta-analysis of oral immunotherapy effect on food allergy-related quality of life","volume":"80","author":"Rosser","year":"2025","journal-title":"Allergy"},{"key":"B12","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1111\/all.16345","article-title":"EAACI guidelines on the management of IgE-mediated food allergy","volume":"80","author":"Santos","year":"2025","journal-title":"Allergy"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s40521-019-00205-2","article-title":"Risk factors for adverse reactions during OIT","volume":"6","author":"Patel","year":"2019","journal-title":"Curr Treat Options Allergy"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.alit.2020.03.008","article-title":"Slow low-dose oral immunotherapy: Threshold and immunological change","volume":"69","author":"Sugiura","year":"2020","journal-title":"Allergol Int"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2025.10.007","article-title":"Peanut oral immunotherapy using 30 mg and 300 mg maintenance doses","author":"Upton","year":"2025","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1016\/j.jaip.2021.12.022","article-title":"Real-world adoption of FDA-approved peanut oral immunotherapy with palforzia","volume":"10","author":"Patrawala","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2020.26.5.620","article-title":"The effectiveness and value of oral immunotherapy and viaskin peanut for peanut allergy","volume":"26","author":"Tice","year":"2020","journal-title":"J Manag Care Spec Pharm"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacig.2022.05.006","article-title":"Protocol design and synopsis: Omalizumab as Monotherapy and as Adjunct Therapy to Multiallergen OIT in Children and Adults with Food Allergy (OUtMATCH)","volume":"1","author":"Wood","year":"2022","journal-title":"J Allergy Clin Immunol Glob"},{"key":"B19","doi-asserted-by":"publisher","first-page":"EVIDoa2400306","DOI":"10.1056\/EVIDoa2400306","article-title":"Peanut oral immunotherapy in children with high-threshold peanut allergy","volume":"4","author":"Sicherer","year":"2025","journal-title":"NEJM Evid"},{"key":"B20","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.anai.2025.03.001","article-title":"The use of grocery-sourced real-food solutions in sublingual immunotherapy for food allergies","volume":"135","author":"Williams","year":"2025","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1016\/j.jaip.2025.02.004","article-title":"Efficacy and safety of epicutaneous immunotherapy in peanut-allergic toddlers: open-label extension to EPITOPE","volume":"13","author":"Greenhawt","year":"2025","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1016\/j.jaci.2019.07.030","article-title":"Long-term sublingual immunotherapy for peanut allergy in children: Clinical and immunologic evidence of desensitization","volume":"144","author":"Kim","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1016\/j.jaci.2020.11.027","article-title":"Epicutaneous immunotherapy for treatment of peanut allergy: Follow-up from the Consortium for Food Allergy Research","volume":"147","author":"Scurlock","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1016\/j.jaip.2021.11.017","article-title":"Safety of epicutaneous immunotherapy in peanut-allergic children: REALISE randomized clinical trial results","volume":"10","author":"Pongracic","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B25","doi-asserted-by":"publisher","first-page":"2447","DOI":"10.1016\/j.jaip.2024.05.007","article-title":"Food sublingual immunotherapy: safety and simplicity of a real food updosing protocol","volume":"12","author":"Windom","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B26","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1002\/alr.23086","article-title":"Sublingual immunotherapy persistence and adherence in real-world settings: A systematic review","volume":"13","author":"Park","year":"2023","journal-title":"Int Forum Allergy Rhinol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.jaci.2023.08.032","article-title":"Desensitization and remission after peanut sublingual immunotherapy in 1- to 4-year-old peanut-allergic children: A randomized, placebo-controlled trial","volume":"153","author":"Kim","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1016\/j.jaip.2025.02.024","article-title":"Long-term safety of epicutaneous immunotherapy in peanut-allergic children: an open-label active treatment (REALISE study)","volume":"13","author":"Pongracic","year":"2025","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2020.06.028","article-title":"Long-term, open-label extension study of the efficacy and safety of epicutaneous immunotherapy for peanut allergy in children: PEOPLE 3-year results","volume":"146","author":"Fleischer","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2025.04.002","article-title":"Efficacy and safety of epicutaneous immunotherapy in children with peanut allergy with atopic comorbidities","volume":"135","author":"Scurlock","year":"2025","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1016\/j.jaip.2024.02.024","article-title":"Safety and effectiveness of bypassing oral immunotherapy buildup with an initial phase of sublingual immunotherapy for higher-risk food allergy","volume":"12","author":"Soller","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2011.04.009","article-title":"Rapid oral desensitization in combination with omalizumab therapy in patients with cow's milk allergy","volume":"127","author":"Nadeau","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1016\/j.jaci.2016.08.010","article-title":"Omalizumab facilitates rapid oral desensitization for peanut allergy","volume":"139","author":"MacGinnitie","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1186\/s13223-020-00419-z","article-title":"Protocol for a double-blind, randomized controlled trial on the dose-related efficacy of omalizumab in multi-food oral immunotherapy","volume":"16","author":"Langlois","year":"2020","journal-title":"Allergy Asthma Clin Immunology: Off J Can Soc Allergy Clin Immunol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/S2468-1253(17)30392-8","article-title":"Anti-IgE treatment with oral immunotherapy in multifood allergic participants: a double-blind, randomised, controlled trial","volume":"3","author":"Andorf","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"AB457","DOI":"10.1016\/j.jaci.2024.12.1061","article-title":"Impact of dupilumab on food-specific IgE levels in food-allergic patients","volume":"155","author":"Lothamer","year":"2025","journal-title":"J Allergy Clin Immunol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"e12381","DOI":"10.1002\/clt2.12381","article-title":"Dupilumab induces a significant decrease of food specific immunoglobulin E levels in pediatric atopic dermatitis patients","volume":"14","author":"van der Rijst","year":"2024","journal-title":"Clin Transl Allergy"},{"key":"B38","doi-asserted-by":"publisher","first-page":"e70002","DOI":"10.1002\/clt2.70002","article-title":"GA(2)LEN ANACARE consensus statement: Potential of omalizumab in food allergy management","volume":"14","author":"Zuberbier","year":"2024","journal-title":"Clin Transl Allergy"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.131347","article-title":"Phase 2a randomized, placebo-controlled study of anti-IL-33 in peanut allergy","volume":"4","author":"Chinthrajah","year":"2019","journal-title":"JCI Insight"},{"key":"B40","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.jaci.2025.05.014","article-title":"Introduction of allergenic foods after treatment with omalizumab","volume":"156","author":"Dantzer","year":"2025","journal-title":"J Allergy Clin Immunol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3390\/nu16162797","article-title":"Dupilumab as therapeutic option in polysensitized atopic dermatitis patients suffering from food allergy","volume":"16","author":"Sernicola","year":"2024","journal-title":"Nutrients"},{"key":"B42","volume-title":"Prescribing information","year":""},{"key":"B43","volume-title":"Prescribing information","year":""},{"key":"B44","volume-title":"Prescribing information","year":""},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1001\/jamapediatrics.2023.0142","article-title":"Timing of allergenic food introduction and risk of immunoglobulin E\u2013mediated food allergy: A systematic review and meta-analysis","volume":"177","author":"Scarpone","year":"2023","journal-title":"JAMA Pediatrics"},{"key":"B46","doi-asserted-by":"publisher","first-page":"e70035","DOI":"10.1111\/pai.70035","article-title":"Diversity of complementary diet and early food allergy risk","volume":"36","author":"Bod\u00e9n","year":"2025","journal-title":"Pediatr Allergy Immunol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1111\/all.14690","article-title":"EAACI Biologicals Guidelines-dupilumab for children and adults with moderate-to-severe atopic dermatitis","volume":"76","author":"Agache","year":"2021","journal-title":"Allergy"},{"key":"B48","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1111\/all.14425","article-title":"EAACI Biologicals Guidelines-Recommendations for severe asthma","volume":"76","author":"Agache","year":"2021","journal-title":"Allergy"},{"key":"B49","doi-asserted-by":"publisher","first-page":"100695","DOI":"10.1016\/j.waojou.2022.100695","article-title":"Long-term effectiveness and safety of omalizumab in pediatric and adult patients with moderate-to-severe inadequately controlled allergic asthma","volume":"15","author":"Hanania","year":"2022","journal-title":"World Allergy Organ J"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.37349\/eaa.2024.00047","article-title":"Long-term evaluation of omalizumab therapy in patients with severe allergic asthma","volume":"2","author":"Bergmann","year":"2024","journal-title":"Explor Asthma Allergy"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2022.08.026","article-title":"Attenuating the atopic march: Meta-analysis of the dupilumab atopic dermatitis database for incident allergic events","volume":"151","author":"Geba","year":"2023","journal-title":"J Allergy Clin Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1746790\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T05:29:48Z","timestamp":1767590988000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1746790\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,5]]},"references-count":51,"alternative-id":["10.3389\/fimmu.2025.1746790"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1746790","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,5]]},"article-number":"1746790"}}